Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., reducing the maximum payout from $125 million to $65 million and accelerating $42.6 million in upfront payments, extending its cash runway into Q4 2027.
Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., reducing the maximum payout from $125 million to $65 million and accelerating $42.6 million in upfront payments, extending its cash runway into Q4 2027.